Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of BBT-877 in idiopathic pulmonary fibrosis
MOH_2022-09-14_012051Phase 2Active, not recruiting
- Sponsor
- Bridge Biotherapeutics
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing BBT-877 with Placebo (2 arms). Primary endpoint: Change in forced vital capacity. Started Sep 2022; status: active, not recruiting.
02
Drugs
LCB17-0877
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on MOH_2022-09-14_012051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-14_012051.